Blood proteins may reveal clues about schizoaffective disorder
NCT ID NCT07447960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure levels of two proteins, LRFN5 and OLFM4, in the blood of 120 people—some with schizoaffective disorder and some healthy. Researchers want to see if these proteins are linked to symptoms, overall function, and inflammation. The goal is to better understand the biology of this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could point toward new biomarkers for schizoaffective disorder, potentially aiding diagnosis or treatment monitoring.
- What could go wrong
- This is an early observational study with no intervention, so it cannot prove cause or lead directly to a treatment. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ, Elâzığ, 23200, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Brain training and exercise from home: a new hope for early schizophrenia?
- Blood inflammation may hold clues to psychiatric diagnosis
- Brain scans probe why social pleasure fades after psychosis
- Can a tailored self-management program improve health outcomes for those with serious mental illness?